PatientsVille.com Logo

NERVOUSNESS and Phentermine

PatientsVille

NERVOUSNESS Symptoms and Causes

Fear and anxiety are part of life. You may feel anxious before you take a test or walk down a dark street. This kind of anxiety is useful - it can make you more alert or careful. It usually ends soon after you are out of the situation that caused it. But for millions of people in the United States, the anxiety does not go away, and gets worse over time. They may have chest pains or nightmares. They may even be afraid to leave home. These people have anxiety disorders. Types include

  • Panic disorder
  • Obsessive-compulsive disorder
  • Post-traumatic stress disorder
  • Phobias
  • Generalized anxiety disorder

Treatment can involve medicines, therapy or both.

NIH: National Institute of Mental Health

Check out the latest treatments for NERVOUSNESS

NERVOUSNESS treatment research studies

Phentermine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Phentermine Side Effects

Pain (28)
Dyspnoea (27)
Anxiety (26)
Chest Pain (22)
Deep Vein Thrombosis (20)
Nausea (19)
Abdominal Pain (18)
Headache (16)
Blood Pressure Increased (16)
Abdominal Pain Upper (16)
Mitral Valve Incompetence (15)
Cholelithiasis (15)
Cholecystitis Chronic (14)
Pulmonary Embolism (14)
Injury (13)
Vomiting (13)
Ventricular Fibrillation (13)
Myocardial Infarction (13)
Loss Of Consciousness (12)
Dizziness (12)
Colitis Ischaemic (11)
Cardiac Arrest (11)
Gallbladder Disorder (10)
Fatigue (10)
Insomnia (10)
Cerebrovascular Accident (9)
Hypertension (9)
Arteriospasm Coronary (9)
Palpitations (8)
Confusional State (8)
Chest Discomfort (7)
Convulsion (7)
Hypotension (7)
Emotional Distress (7)
Feeling Abnormal (7)
Asthenia (6)
Abnormal Behaviour (6)
Diarrhoea (6)
Pain In Extremity (6)
Hypoaesthesia (6)
Tricuspid Valve Incompetence (6)
Hypercoagulation (5)
Alanine Aminotransferase Increased (5)
Mental Disorder (5)
Heart Rate Increased (5)
Pneumomediastinum (5)
Ventricular Tachycardia (5)
Respiratory Arrest (5)
Pyrexia (5)
Migraine (5)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

.. Worry over whether I'll be accepted by students and colleagues as normal, OPK, even competenty. 2. Worry about death of pets, spouse, getting critically ill myself 3. Dissatisfaction wqith the job I do teaching and that student

Burning arms,feet,legs,hands and very nervous over my body after the burning the tingling start.

I have many 9th grade presentations to do in Multimedia class. and I get REALLY nervous, cause afterwards I feel sick in the stomach.... I'm fine during Marching for my school's band or being on stage with a friend, but when it comes to being alone

<b>drowsy, insomnia, slight palpitation, nervousness</b>.

After taking tofranil last night i experienced an unusual feeling when i woke up.it was as though blood was rushing to my head though it didn't cause me nervousness. it weas when i got out of bed that i was feeling some kind of anxiety .when i checke

How long do I need to take this concor 5mg? is it a life long intake now? My problem was hypertension, nervousness and anxiety and also my thyroid test showed elevated level which came back to normal without any medication, after medication i am fee

I am recovering from a night in the hospital after using MUCINEX DM.I was using it for 4 days. Each time I took it I had dizziness, nausea and lightheadedness, as well as nervousness and nightmares. It was helping my congestion, so my husband insiste

I had Anxiety and i had dizziness and i also had nervousness and i had tremors.This medcine is bad/And i stiill have the side effects and trying to get help now.i will never take MucinexDM ever again.

I have been off cytomel for 4 weeks and still have nervousness, tremor, muscle rigidity an sleep disturbances. When can I expect this to improve?

I have been using a generic version of Flonase on and off since 3 months ago, but starting about a week ago I started having dizziness as well as nervousness and even fainting feelings. At 1st I thought this was part of a recent cold or hay fever, bu

I started using the generic version of Flonase 4 days ago. Yesterday I began to experience severe dizziness, nervousness, faint feelings. I am an RN and checked my blood pressure and heart and these are all normal. I discontinued the Flonase and

I took it at about 9:30 pm, then I went to bed. I awoke at about 2:30 with an unexplained nervousness and had trouble getting back to bed. Not realizing it was the medicine, I again took it the next night at around the same time.&

I took mucinix dm almost a month ago..i now suffer severe nervousness anxiety.and also at 32 went from perfect bp..to now being on bloodpressure medcine because when I arrived at the doctor my resting heartache was134 I have not been the same since

NERVOUSNESS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Vagotonic Effect of Remifentanil and Autonomic Nervous System Activity.
Conditions: Autonomic Nervous Sytem Activity;   Inluence of Remifentanil on Autonomic Nervous System
Intervention: Drug: Remifentanil
Outcome Measure: Vagomimetic effect of RMFNT in reference to autonomic nervous system activity
2 Recruiting Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Condition: Malignant Solid Tumor - Malignant Nervous System Neoplasm
Intervention: Drug: Cabazitaxel (XRP6258)
Outcome Measures: Maximally tolerated dose of cabazitaxel;   Antitumor activity by evaluating the objective response rate (ORR) for patients with recurrent or refractory high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG);   Number of adverse events for patients with recurrent or refractory solid tumors including tumors of the central nervous system;   Pharmacokinetics: AUC;   Pharmacokinetics: CL;   Pharmacokinetics: Vss;   Pharmacokinetics: Cmax;   Preliminary anti-tumor activity in patients with recurrent or refractory tumors of the central nervous system;   Progression free survival in patients with recurrent or refractory HGG or DIPG;   Overall survival in patients with recurrent or refractory HGG or DIPG
3 Unknown  Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Condition: Central Nervous System Tumors
Interventions: Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Temozolomide
Outcome Measures: To conduct a phase I study to evaluate the safety of this combination of chemotherapy agents.;   To determine the response of children with recurrent or refractory central nervous system tumors with this combination of chemotherapy agents.;   To compare the response and toxicity with historical controls with the same disease.;   To estimate the 2 and 5 year survival with children treated with this regimen.;   To provide safety and efficacy data for to recommend further larger studies.
4 Recruiting Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Conditions: Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions: Genetic: DNA analysis;   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8;   Radiation: 131I-3F8
Outcome Measures: Six-month overall survival;   response rate;   cumulative toxicities
5 Recruiting Rituximab&Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL
Conditions: Primary Central Nervous System Lymphoma;   Brain and Central Nervous System Tumors;   Lymphoma
Interventions: Drug: Rituxan;   Drug: Carboplatin;   Drug: Methotrexate;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Leucovorin
Outcome Measures: Complete response rate;   Overall survival at 2 years;   Event-free survival at 2 years
6 Recruiting MyChoice: An Application of the TFEQ-R18v2
Condition: Central Nervous System Neoplasms
Interventions: Behavioral: Three-Factor Eating Questionnaire (TFEQ)-R18v2;   Behavioral: Multifactor Screener;   Behavioral: Eating Questionnaire-EMA (EQ-EMA)
Outcome Measure: Factor Structure Comparisons of Eating Questionnaires
7 Recruiting The Autonomic Nervous System and Obesity
Conditions: OBESITY;   HYPERTENSION;   PURE AUTONOMIC FAILURE;   SHY-DRAGER SYNDROME
Interventions: Drug: Trimethaphan;   Drug: Pseudoephedrine
Outcome Measures: Change in supine systolic blood pressure after achieving complete ganglionic blockade.;   Change in resting energy expenditure after achieving complete autonomic blockade.
8 Recruiting Alleviating the Metabolic Side Effects of Antipsychotic Medications
Condition: Schizophrenia
Interventions: Drug: Moxonidine;   Drug: Placebo
Outcome Measures: To determine the association between sympathetic nervous system and metabolic abnormalities (eg, weight gain) observed with antipsychotic treatment.;   Change from baseline in sympathetic nervous system activity.
9 Recruiting Longitudinal Study of Biomarkers
Condition: Central Nervous System Tumor
Intervention:
Outcome Measure: Presence of microRNAs and proteins in the blood, cerebrospinal fluid and urine of patients with central nervous system tumors from diagnosis through the course of their treatment
10 Recruiting Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
Conditions: Multiple Sclerosis;   Autonomic Nervous System
Intervention: Drug: Gilenya
Outcome Measures: RMSSD;   HRV
11 Recruiting Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Conditions: Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma
Interventions: Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide
Outcome Measures: 3-year PFS rate with NGGCT;   PFS distribution of localized CNS germinoma;   Neurocognitive function using the ALTE07C1 protocol;   Estimation of the PFS distribution of patients with NGGCT treated with IFR;   Estimation of the OS distribution of patients with NGGCT treated with IFR assessed;   Estimation of the PFS distribution of patients with localized germinoma patients and CSF serum hCGβ of 50 mIU/mL or less or CSF serum hCGβ greater than 50 mIU/mL and less than or equal to 100 mIU/mL;   Estimation of the OS distribution of patients with localized germinoma patients and CSF serum hCGβ of 50 mIU/mL or less or CSF serum hCGβ greater than 50 mIU/mL and less than or equal to 100 mIU/mL
12 Recruiting Autonomic Nervous System and Exercise In Gestational Diabetes
Conditions: Gestational Diabetes;   Cardiovascular Risk Factors
Interventions: Other: individual exercise;   Other: general exercise
Outcome Measures: Heart Rate Variability;   VO2max;   autonomic nervous system function;   quality of life;   mental health
13 Recruiting [11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease
Condition: Parkinson's Disease
Intervention: Other: [11C]donepezil PET
Outcome Measure: Distribution volume of [11C]donepezil in internal organs
14 Recruiting Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Conditions: Central Nervous System Disease;   Multiple Sclerosis
Intervention:
Outcome Measures: Diagnostic Study - Definite diagnosis of MS or another disorder. Follow-Up Study - Disease progession as assessed by clinical and MRI criteria.;   Clinical measures of disability (EDSS, NRS, MSFC): MRI measures of lesions and CNS tissue destruction (T2LL, T1LL and calculated black hole fraction, measures of atrophy); and immunological biomarkers.
15 Recruiting The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
Condition: Radiation Necrosis
Intervention: Drug: Bevacizumab (Avastin®)
Outcome Measures: Feasibility of treating pediatric patients with CNS radiation necrosis with bevacizumab;   Collect multiple aspects of the patient's clinical status and radiologic imaging
16 Recruiting Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Condition: Radiation Therapy
Intervention:
Outcome Measure:
17 Unknown  Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer
Conditions: Brain Disease;   Metastasis;   Lung Cancer
Intervention:
Outcome Measures: Central nervous system metastasis development;   Death
18 Recruiting Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity
Condition: Metabolic Syndrome
Interventions: Drug: Pioglitazone;   Drug: sugar pill
Outcome Measures: Sympathetic nervous system activity, measured as muscle sympathetic nervous activity and whole-body noradrenaline spillover;   Baroreflex function, adrenoceptor expression
19 Recruiting Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Conditions: Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Lymphoma;   Neurotoxicity;   Radiation Toxicity
Interventions: Biological: rituximab;   Drug: cytarabine;   Drug: methotrexate;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Radiation: whole-brain radiation therapy
Outcome Measures: Progression free survival (PFS) defined as the interval from randomization to progression or death, whichever occurs first;   Overall survival (OS) defined as the interval from randomization to death due to any cause;   Response rate (partial response or complete response);   Quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core/Brain Cancer Module (QLQ-C30/BCM20);   Neurocognitive function measured by the Hopkins Verbal Learning Test-Revised (HVLT-R), Trail Making Test Part A, Trail Making Test Part B, Controlled Oral Word Association Test (COWAT)
20 Not yet recruiting Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Agomelatine;   Drug: Escitalopram
Outcome Measures: Change from baseline in markers of sympathetic nervous system activity.;   Change from baseline in the magnitude of morning surge in blood pressure.;   To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.;   Change from baseline in insulin resistance.;   Change from baseline on markers of cardiac risk.